DelistingSep 25, 2026, 04:27 PM
Silexion Therapeutics Faces Nasdaq Delisting Warning Over Low Share Price
AI Summary
Silexion Therapeutics Corp (SLXN) announced it received a notification from Nasdaq indicating a deficiency in its closing bid price, which has been below the $1.00 minimum for 30 consecutive business days. The Nasdaq hearings panel will review this deficiency to determine the company's continued listing status on the Nasdaq Capital Market. The notification does not have an immediate impact on the trading of the company's ordinary shares or warrants.
Key Highlights
- Silexion Therapeutics Corp received a notification from Nasdaq regarding a bid price deficiency.
- The closing bid price of the Company’s ordinary shares was below the minimum $1.00 requirement for 30 consecutive business days.
- The Nasdaq hearings panel will consider the deficiency in its decision regarding continued listing on the Nasdaq Capital Market.
- The notification has no immediate effect on the trading of ordinary shares or warrants.
Price Impact
More from SLXN